This post has been archived and contains information that may be out of date.
The Centers for Medicare & Medicaid Services (CMS) has issued a final rule rescinding the Most Favored Nation (MFN) drug pricing model.
The MFN rule would have required CMS to pay the lowest price paid by any comparable Organisation for Economic Co-operation and Development country for at least 50 separately payable Medicare Part B drugs. All Medicare providers and suppliers that receive separate Medicare Part B fee-for-service payment for the model’s included drugs, with certain exceptions, would have been required to participate.
